Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.82% 54.00p 53.00p 55.00p 55.00p 53.50p 55.00p 260,746.00 10:54:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -4.5 -3.7 - 65.14

Futura Medical Share Discussion Threads

Showing 14351 to 14375 of 14375 messages
Chat Pages: 575  574  573  572  571  570  569  568  567  566  565  564  Older
DateSubjectAuthorDiscuss
25/3/2017
14:14
http://www.fool.co.uk/investing/2017/03/23/2-stocks-with-great-dividend-and-growth-potential/
lbo
25/3/2017
11:58
AGM in June
mikethebike4
24/3/2017
13:10
http://www.proactiveinvestors.co.uk/companies/stocktube/7158/futura-medical-continuing-to-make-good-progress-across-its-portfolio-of-products--7158.html
lbo
23/3/2017
15:17
Year ended Year ended 31 December 31 December 2016 2015 GBP GBP Middle East / ROW 118,192 - United States of America 35,473 3,237 Europe 16,697 26,239 170,362 29,476 The one bright spot in the above seems to be the middle east - perhaps 'the lads' need a lot of help out there but what has happened to Blue Diamond in Europe I don't know - gone from £26k in 2015 to £16K in 2016 - perhaps all those blokes in Benelux are studs and don't need assistance with anything ! mtb4
mikethebike4
23/3/2017
15:11
The Group has tax losses of GBP22,332,102 (2015: GBP20,360,259) available for offset against future taxable profits. Currently this is the one definite silver lining in the whole situation - all Futura needs to do to realise this advantage is to make profits !! Remember Mr. Barder, Futura is not just a development company it is a sales company and ultimately will live or die by its selling expertise mtb4
mikethebike4
23/3/2017
13:43
Motley Fool.....Growth star in the making?Turning to the growth front, Futura Medical (LSE: FUM) is a possible pharmaceuticals and biotechnology winner with interesting prospects.It's big in the field of erectile dysfunction with its Eroxon candidate having "the potential to be the world's fastest-acting treatment for ED", and its aspirations are supported by a "novel erectogenic condom". Oh, and it does pain-relief stuff too.The erectile dysfunction gel is certainly good at getting the share price up - it caused a surge back in September 2016 when Futura announced "breakthrough results" from early trials and spoke of a potential $5bn market. Thursday's full-year update continued the enthusiasm, telling us the firm intends to "begin a Phase III placebo-controlled parallel group multi-centre clinical study of 700 or more patients in Q4 2017?.An investment in a company like this, which is not generating profits yet, is definitely not to be undertaken lightly. Indeed, far from a profit, Futura recorded a net loss of £3.7m for the year - though that is down from 2015's loss of £5.08m, thanks to lower spending on clinical trials.On the bright side, a share placing in November raised £12m for the coffers, and at 31 December the company had cash resources of £12.35m.That looks like a reasonably healthy position to me at this stage in the company's development, but medical progress can be painfully slow and we really can't tell how long it will be (assuming a successful Phase III and eventual clinical approval) before sales start ramping up enough to achieve profits.So Futura Medical is still a risky investment, but if you can live with that I'd say it's one of the more promising of its kind that I've seen recently.
j777j
23/3/2017
11:43
It may suit Barder et al as they have been getting paid for year after year. I reckon in 5 years time you could be listening to the same old stuff ie the company is working hard to commercialise its products Investing in this at the start was madness -you get diluted away and nothing happens for 10 years! The idea that you are somehow in early on something and will benefit accordingly is rubbish -in fact the early (on float) and supportive investors are the ones who get shafted the most. Best to trade on the speculative froth at the start as people think of the potential or just before it it starts to generate some decent cashflows.
meijiman
23/3/2017
11:30
jb the problem is that if nobody invests at the start companies never get off the ground I am actually slightly in profit at this level but my money has been tied up for years while I have been listening to Barder in anticipation that this year will be the one ! the products are very good but actually selling them does not seem to be very high up on the boards list of priorities - they seem to be happy getting all these deals set up but most are so far non-prforming. I think it is highly likely that by concentrating on current (standard) condom suppliers they are talking to people with a vested interest in selling their existing lines and are tying up in these agreements what are industry disruptive products. They should have gone for smaller dynamic, penetrative (sorry about the pun) companies from the start. Basically they have been taken for suckers. mtb4
mikethebike4
23/3/2017
11:25
"Working to enable launch in selected markets". It sounds vague, I agree. Problem being that Church & Dwight do not want competition to know if, when and where they're going to launch a new product. We just have to deal with that. Maybe there is a big US launch planned very soon. We just don't know, it's wait and see.
greedfear
23/3/2017
10:50
Analysts presentation and Q&A seems to suggest a lot of background work is going on with Church & Dwight regarding CSD500 launches. Futura expect launches in multiple territories this year. I suspect the UK will be one of them and will be under the Trojan Amplify brand name. They know how to package and market standard condoms so one can only imagine what they have planned for CSD500 http://nypost.com/2017/03/22/trojan-unveils-condom-campaign-aimed-at-women/
lbo
23/3/2017
10:43
All hindsight MBT4, I get you totally.. all been there but learn with experience These Cos are like miners... development and delivery phase are the same. Risks are high early on, but as these move to next phases , it de-rsisks bit by bit Ppl get in too early, but those are trading opportunities The final phase to commercialisation or production is when one should be investing Will power to hold is the key to making big returns What stage is FUM at for you ? Does an investment as this time warrant holding now ?
jailbird
23/3/2017
10:28
- 'working to enable launch in selected markets' hardly fills me with confidence" Pure speculation, as it could also be a huge market. Strange time to be losing patience with the co.16 years later and things are looking rather interesting.
j777j
23/3/2017
10:02
J7 - I've edited my post to help you with what I'm on about. No textual change. Ref C&D - 'working to enable launch in selected markets' hardly fills me with confidence they're planning a major push in the near future. It looks like another two years or more before FUM will get serious revenue from the US. I can't help thinking that rather than licensing to the largest existing supplier they'd have been better off going with a more aggressive number two or three.
supernumerary
23/3/2017
09:52
LBO who pays singers fee ? jb As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated. All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day ! MTB4
mikethebike4
23/3/2017
09:44
Agree seems to show a complete misunderstanding of what this co is about. The size of their addressable markets could be bringing annual royalties more than the current mkt cap within the next couple of years. Never understand why people who don't like a co don't simply move on. Re the post above,they have already licenced the dicloflenac topical gel for the UK,so not quite sure what you are talking about. Futura Medical plc ("Futura" or the "Company") Signs UK Licensing Agreement in Pain Relief Futura Medical plc (AIM: FUM), the innovative healthcare company focused on transdermal technology, is pleased to announce that it has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG ("STADA"), the international healthcare group, for the commercialisation of TPR100, the Company's novel diclofenac gel for pain relief. The licensing agreement was signed with Huddersfield-based Thornton & Ross Ltd, which was acquired by STADA three years ago and is one of the largest consumer health companies in the UK. Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK. Futura will receive an upfront payment and milestone payments up to a certain limit along with royalties on product sales. Further financial or other details are not being disclosed. Re the condom they are still waiting for EU regulatory approval on extended shelf life,however" Church & Dwight, our CSD500 distribution partner for North America and key countries in Europe, is currently working to enable launch in selected markets."
j777j
23/3/2017
09:42
They really need to get the condom selling in the bigger markets - Church & Dwight seem to have been shilly-shallying for ever. Also somewhat disappointing that there's no progress overseas with the topical pain relief gel. No licensees, and no plans to progress it without them. Could do with a real kick-start...
supernumerary
23/3/2017
09:42
You are very frustrated mbt4Yes it takes years to bring drugs and medicines to market, that goes without saying and not just applies to FUM.To have highly disruptive ones is an amazing achievement
jailbird
23/3/2017
09:36
Revenue was actually above what Singer forecast for the year and they are forecasting over £2m this year.https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical/research/n-1-singer/n-1-singer-futura-medical-fy-results-continued-clinical-regulatory-and-commercial-progress/CC5_10_1
lbo
23/3/2017
09:03
more of the 'jam tomorrow' I'm afraid - how many years has this been going on ? revenue is the only thing that really counts :- Year ended Year ended 31 December 31 December 2016 2015 GBP GBP Middle East / ROW 118,192 - United States of America 35,473 3,237 Europe 16,697 26,239 total 170,362 29,476 £170K just about covers 1/10th of wages & emoluments - nothing else Just as well we had that fund-raising in November (£12mil) as that is all that's left cash-wise It's all very well having all these licenses but most are not underway yet and 'sales' would appear to be miniscule mtb4
mikethebike4
23/3/2017
07:34
All on course, boys.
montyhedge
23/3/2017
07:27
They spent £4 million last year So Co is financially sound for cash with £12m in the bank R&D is reducing as nowPhase lll for med2002 is main cost now
jailbird
23/3/2017
07:25
This Co is should already be worth more than it's market cap based on its world class portfolio The topical applications make this first choice treatment These are better than all oral treatments like Viagra and other pain killers which ppl with other health issues cannot take ... so it adds another market of ppl previously unattainable to these type of medicine products This Co will be huge, with Cos wanting to license their Portfolio
jailbird
22/3/2017
17:13
Oh well, 1/2p is better than a kick up the b*m mtb4
mikethebike4
22/3/2017
13:15
Looks as if the plan is to agree licences on a country by country basis - even if regional I'd have expected an Iberian one to include Spain. Will have to wait until the interims in sept to try and see what the financial impact of these 8 (so far) is..
sportbilly1976
22/3/2017
08:48
no great reaction to share price - Portugal is only a small country where in the world are these 8 licences ? mtb4
mikethebike4
Chat Pages: 575  574  573  572  571  570  569  568  567  566  565  564  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170326 13:07:48